Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus.
Endothelial dysfunction is frequently found in diabetic subjects . This study was performed to investigate whether atorvastatin therapy was able to reverse endothelial dysfunction in type 2 diabetes and , if so , whether the effect was due to its antiinflammatory action . Eighty patients ( baseline low density lipoprotein , 4.37 + /- 0.71 mmol/liter ) were r and omized to atorvastatin ( 10 mg daily for 3 months , followed by 20 mg daily for 3 months ) or placebo in a double blind study . Endothelial function was assessed by high resolution vascular ultrasound , and high sensitivity C-reactive protein ( CRP ) was assessed by immunoturbidimetric assay . Diabetic patients had higher CRP ( P < 0.01 ) than matched nondiabetic controls , and both endothelium-dependent and independent vasodilation were impaired ( P < 0.01 ) . Atorvastatin ( 10 and 20 mg ) lowered plasma cholesterol by 32.9 % and 38.0 % , triglyceride by 15.4 % and 23.1 % , and low density lipoprotein by 43.4 % and 50.1 % , respectively . At 6 months , plasma CRP decreased in the atorvastatin group compared with baseline ( P < 0.05 ) . Endothelium-dependent vasodilation improved in the atorvastatin group compared with the placebo group ( P < 0.05 ) . The percent change in endothelium-dependent vasodilation at 6 months correlated with the percent change in CRP ( r = -0.44 ; P < 0.05 ) , but not with changes in plasma lipids . In conclusion , treatment with atorvastatin in type 2 diabetes led to a significant improvement in endothelium-dependent vasodilation , which might be partly related to its anti-inflammatory effect
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .